Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for the production of prostaglandins. By lowering prostaglandin levels, it reduces pain signalling, lowers elevated body temperature, and diminishes the inflammatory response.

The specific dose and infusion rate of Ibuprofen B. Braun are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Healthcare providers follow local guidelines and product labeling to set the appropriate regimen.

The safety of ibuprofen in pregnancy is not well established, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as ibuprofen can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other IV NSAIDs such as ketorolac, ibuprofen offers a similar analgesic and antipyretic profile but may have a slightly lower risk of renal toxicity at equivalent doses. Unlike opioid analgesics, ibuprofen does not cause respiratory depression, making it a useful component of multimodal pain management.

Ibuprofen B. Braun should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, the solution should be inspected for particulate matter and discoloration, and any unused portion should be discarded according to local regulations.

The product is given as an intravenous infusion, typically diluted in compatible IV fluids and administered over a short period as directed by the prescriber. Administration should be performed by qualified healthcare personnel using aseptic technique and appropriate infusion equipment.

Serious risks include severe allergic reactions such as anaphylaxis, gastrointestinal bleeding or ulceration, acute kidney injury, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored for signs of these events, especially if they have pre‑existing risk factors.

Ibuprofen B. Braun is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal bleeding, severe uncontrolled hypertension, advanced heart failure, and in the third trimester of pregnancy. Clinicians should also avoid use in patients with significant renal impairment unless benefits outweigh risks.